SG11202102126VA - Alternative processes for the preparation of tubulysins and intermediates thereof - Google Patents
Alternative processes for the preparation of tubulysins and intermediates thereofInfo
- Publication number
- SG11202102126VA SG11202102126VA SG11202102126VA SG11202102126VA SG11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA
- Authority
- SG
- Singapore
- Prior art keywords
- tubulysins
- intermediates
- preparation
- alternative processes
- alternative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862728639P | 2018-09-07 | 2018-09-07 | |
PCT/US2019/050023 WO2020051503A1 (fr) | 2018-09-07 | 2019-09-06 | Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102126VA true SG11202102126VA (en) | 2021-04-29 |
Family
ID=68000124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102126VA SG11202102126VA (en) | 2018-09-07 | 2019-09-06 | Alternative processes for the preparation of tubulysins and intermediates thereof |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230002440A1 (fr) |
EP (1) | EP3847161A1 (fr) |
JP (1) | JP7511543B2 (fr) |
KR (1) | KR20210073525A (fr) |
CN (1) | CN112996778A (fr) |
AU (1) | AU2019336231A1 (fr) |
BR (1) | BR112021004317A2 (fr) |
CA (1) | CA3111149A1 (fr) |
EA (1) | EA202190699A1 (fr) |
IL (1) | IL281090A (fr) |
MA (1) | MA53550A (fr) |
MX (1) | MX2021002570A (fr) |
SA (1) | SA521421375B1 (fr) |
SG (1) | SG11202102126VA (fr) |
TW (1) | TWI825169B (fr) |
WO (1) | WO2020051503A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723671C (fr) * | 2007-05-10 | 2018-06-19 | R & D Biopharmaceuticals Gmbh | Derives de tubulysine |
IT1394860B1 (it) | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
WO2017096311A1 (fr) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugués de composés de tubulysine quaternisés |
CA3073766A1 (fr) | 2017-09-08 | 2019-03-14 | Seattle Genetics, Inc. | Procede de preparation de tubulysines et d'intermediaires de celles-ci |
-
2019
- 2019-09-06 CN CN201980071734.XA patent/CN112996778A/zh active Pending
- 2019-09-06 SG SG11202102126VA patent/SG11202102126VA/en unknown
- 2019-09-06 EA EA202190699A patent/EA202190699A1/ru unknown
- 2019-09-06 BR BR112021004317-9A patent/BR112021004317A2/pt unknown
- 2019-09-06 AU AU2019336231A patent/AU2019336231A1/en active Pending
- 2019-09-06 MA MA053550A patent/MA53550A/fr unknown
- 2019-09-06 WO PCT/US2019/050023 patent/WO2020051503A1/fr active Application Filing
- 2019-09-06 TW TW108132162A patent/TWI825169B/zh active
- 2019-09-06 CA CA3111149A patent/CA3111149A1/fr active Pending
- 2019-09-06 KR KR1020217010157A patent/KR20210073525A/ko active Search and Examination
- 2019-09-06 JP JP2021512696A patent/JP7511543B2/ja active Active
- 2019-09-06 US US17/273,693 patent/US20230002440A1/en active Pending
- 2019-09-06 EP EP19773284.5A patent/EP3847161A1/fr active Pending
- 2019-09-06 MX MX2021002570A patent/MX2021002570A/es unknown
-
2021
- 2021-02-24 IL IL281090A patent/IL281090A/en unknown
- 2021-03-03 SA SA521421375A patent/SA521421375B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
TW202024043A (zh) | 2020-07-01 |
CA3111149A1 (fr) | 2020-03-12 |
MA53550A (fr) | 2021-12-15 |
MX2021002570A (es) | 2021-06-08 |
IL281090A (en) | 2021-04-29 |
SA521421375B1 (ar) | 2024-02-11 |
JP2021536475A (ja) | 2021-12-27 |
AU2019336231A1 (en) | 2021-03-18 |
WO2020051503A1 (fr) | 2020-03-12 |
US20230002440A1 (en) | 2023-01-05 |
KR20210073525A (ko) | 2021-06-18 |
EP3847161A1 (fr) | 2021-07-14 |
CN112996778A (zh) | 2021-06-18 |
BR112021004317A2 (pt) | 2021-05-25 |
TWI825169B (zh) | 2023-12-11 |
JP7511543B2 (ja) | 2024-07-05 |
EA202190699A1 (ru) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201902968B (en) | Method for increasing the secretion levels of interleukin 2 and proteins derived from it | |
IL292648A (en) | A process for the preparation of glucuronide-drug binders and their intermediates | |
EP3433278A4 (fr) | Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires | |
IL280922A (en) | Anti-HER2 polypeptides and uses thereof | |
ZA202101214B (en) | Process and intermediates for the preparation of bilastine | |
IL283948A (en) | Methods for treating depression | |
ZA202003590B (en) | Process for the preparation of opicapone and intermediates thereof | |
PT3458467T (pt) | Processo para a epoxidação 6,7-alfa de esteroide-4,6-dienos | |
HUE062956T2 (hu) | Eljárások niraparib és köztitermékei elõállítására | |
IL272837A (en) | A process for preparing tubolysins and their intermediates | |
EP3717456A4 (fr) | Procédé de préparation de roxadustat et de ses intermédiaires | |
IL275655A (en) | A process for the preparation of amino-pyrimidine and its intermediates | |
HUE058259T2 (hu) | Eljárás lubiproszton és annak intermedierei elkészítésére | |
PL3737685T3 (pl) | Sposób wytwarzania kryzaborolu i jego związków pośrednich | |
GB201915447D0 (en) | Polymorphs of avapritinib and methods of preparing the polymorphs | |
IL281090A (en) | Alternative processes for the preparation of tubolysins and their intermediates | |
IL255819A (en) | An improved process for the preparation of sofosbuvir and intermediates | |
IL290169A (en) | Method and intermediates for the preparation of pyroxulfone | |
ZA202107053B (en) | Novel process for the preparation of filgotinib and intermediates thereof | |
IL278549B1 (en) | Intermediates and processes for the preparation of linagliptin and its salts | |
EP3877361C0 (fr) | Procédé de préparation d'arylsulfonylpropènenitriles | |
PT3969459T (pt) | Processo e intermediários para a preparação de eldecalcitol | |
LT4073051T (lt) | Būdas ir tarpinis junginys, skirti oksetan-2-ilmetanamino gavimui | |
PL3704100T3 (pl) | Nowy sposób wytwarzania tawaborolu i jego związków pośrednich | |
HUP1500451A2 (en) | Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates |